

DCAT TOP Industry NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

DCAT
WEEK
2017

OPENING DAY

HAPPY
HOUR

Patheon
A HEALTHIER WORLD. DELIVERED.

Request an invitation

1. [Pharma Company Executives Urge Congress For Business Tax Reforms](#)

A coalition of 16 large companies, including representation from the pharmaceutical, life-sciences and chemical industries, has sent a letter to US Congressional leadership calling for tax reform that would lower the US corporate tax rate and modify the border adjustable tax system in the US. [Read More](#)

2. [Teva Recalls Nearly 500,000 Units of Diabetes Drug](#)

Actavis Inc., part of Teva Pharmaceutical Industries, has issued a Class II voluntarily recall of 499,320 units of glipizide extended-release tablets, 2.5 mg, a drug for treating Type 2 diabetes, due to failed dissolution specifications. Teva acquired Actavis Generics, the generics business of Allergan in 2016. [Read More](#)

3. [Momenta's Generic MS Drug Delayed by Warning Letter to Pfizer](#)

Momenta Pharmaceuticals, which is partnered with Sandoz, the generic drug arm of Novartis, for Glatopa (glatiramer acetate injection), a generic version of Teva Pharmaceutical Industries' blockbuster multiple sclerosis drug, Copaxone, reported a delay in the regulatory review of a 40-mg formulation of the drug due to a manufacturing issue with the contract manufacturer of the fill-finish of the product, Pfizer. Pfizer received a FDA Warning Letter relating for its fill-finish facility in McPherson, Kansas. [Read More](#)

4. [EC OKs Celltrion's Biosimilar to Roche's Top-Selling Cancer Drug](#)

Celltrion Healthcare has received approval from the European Commission for Truxima (rituximab), a biosimilar to Roche's MabThera/Rituxan (rituximab), for all indications of the reference drug in the European Union. MabThera/Rituxan is Roche's top-selling drug with 2016 sales of CHF 7.3 billion (\$7.3 billion). [Read More](#)

5. [Stada Receives \\$3.7 Billion Bid for the Company](#)

Stada Arzneimittel AG, a German pharmaceutical company, has received a bid for acquisition of \$3.7 billion from Advent International, a private-equity firm. Earlier this month, Stada said that it had opened up talks with potential bidders for the company. [Read More](#)

6. [Pfizer's CMO Unit Expands Fill-Finish Services](#)

Pfizer CentreOne, a global contract manufacturing organization within Pfizer, has expanded its fill-finish services at its site in Kalamazoo, Michigan to include vial-filling of sterile suspensions and small molecules and biologics. [Read More](#)

7. [Quotient Acquires Charles River's CDMO Unit](#)

Quotient Clinical has acquired QS Pharma, Charles River Laboratories International's contract development and manufacturing organization unit based near Philadelphia, which gives Quotient capability in high-potency manufacturing. [Read More](#)

8. [FDA OKs AstraZeneca's New Psoriasis Drug](#)

AstraZeneca and Valeant Pharmaceuticals have received FDA approval for Siliq (brodalumab) injection, a new molecular entity for treating moderate-to-severe plaque psoriasis, an inflammatory disease. This news is part of *DCAT Value Chain Insights Drug Approval News*. [Read More](#)

9. [AstraZeneca Licenses Rights to Cancer Drug in \\$320-Million Deal](#)

AstraZeneca has agreed to license the commercial rights to Zoladex (goserelin acetate implant), a cancer drug, in the US and Canada to TerSera Therapeutics in a deal worth up to \$320 million. AstraZeneca receives \$250 million upon completion of the deal and will also receive sales-related milestones totaling up to \$70 million. [Read More](#)

10. [Novasep Opens New ADC Manufacturing Plant](#)

Novasep has opened its new EUR 11-million (\$11.6-million) bioconjugation facility at its site in Le Mans, France, for clinical and commercial manufacturing of antibody-drug conjugates. The 2,000 square-meter facility has two flexible GMP production suites equipped with 10-liter to 400-liter vessels. [Read More](#)

[DCAT Week '17: Next-Generation and Drug Delivery Technologies](#)

Pharmaceutical companies, CDMOs, CMOs and excipient producers need to continually evaluate their strategies, technologies, and capabilities in formulation development, drug delivery, and drug-product manufacturing. How does your company's toolbox measure up? In the DCAT Week '17 Education Program, [Market Opportunities: Advanced Formulation and Next-Generation Drug Delivery Technologies](#), gain perspectives from leading pharma companies and industry experts on what will be required in the near- and long-term. [Read More](#)

[About Top Industry News](#)

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org